Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Patent metadata

Field	Value
Publication number	US-12570959-B2
Application number	US-202217823454-A
Country	US
Kind code	B2
Filing date	Aug 30, 2022
Priority date	Mar 29, 2017
Publication date	Mar 10, 2026
Grant date	Mar 10, 2026

Abstract

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

First claim

What is claimed is:

1 . A method for treating a subject with a cancer, the method comprising administering expanded tumor infiltrating lymphocytes (TILs) comprising:
(a) performing a first expansion by (i) thawing cryopreserved dissociated tumor materials comprising a first population of TILs from a tumor that was resected from the subject, dissociated after the resection, and cryopreserved after the dissociation, and (ii) culturing the first population of TILs in a cell culture medium comprising IL-2, and optionally OKT-3, to produce a second population of TILs, wherein the first expansion is performed in a closed system providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-14 days to obtain the second population of TILs; (b) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, optionally OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-14 days to obtain the third population of TILs, wherein the second expansion is performed in the closed system providing a second gas-permeable surface area, and wherein the transition from step (a) to step (b) occurs without opening the closed system; (c) harvesting the third population of TILs, wherein the harvested third population of TILs is a therapeutic population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the closed system; (d) transferring the harvested third TIL population from step (c) to an infusion bag, wherein the transfer from step (c) to (d) occurs without opening the closed system; (e) cryopreserving the infusion bag comprising the harvested TIL population from step (d) using a cryopreservation process; and (f) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (e) to the subject.

2 . The method of claim 1 , wherein the dissociated tumor materials comprise a tumor digest.

3 . The method of claim 1 , wherein the dissociated tumor materials comprise one or more tumor fragments.

4 . The method of claim 1 , wherein obtaining the dissociated tumor materials comprises mechanically disrupting the tumor resected from the subject.

5 . The method of claim 4 , wherein obtaining the dissociated tumor materials further comprises purifying the disassociated tumor materials using a density gradient separation.

6 . The method of claim 1 , wherein obtaining the dissociated tumor materials comprises enzymatically disrupting the tumor resected from the subject.

7 . The method of claim 6 , wherein the enzymatic disruption is performed in an enzymatic media.

8 . The method of claim 7 , wherein the enzymatic media comprises a mixture of enzymes.

9 . The method of claim 8 , wherein the mixture of enzymes comprises a collagenase.

10 . The method of claim 8 , wherein the mixture of enzymes comprises a DNase.

11 . The method of claim 8 , wherein the mixture of enzymes comprised a collagenase and a DNase.

12 . The method of claim 1 , wherein the third population of TILs harvested in step (c) comprises sufficient TILs for administering the therapeutically effective dosage of the TILs in step (f).

13 . The method of claim 12 , wherein the therapeutically effective dosage of the TILs in step (f) comprises from about 1×10 9 to about 9×10 10 TILs.

14 . The method of claim 12 , wherein the therapeutically effective dosage in step (f) comprises from about 1×10 9 to about 5×10 9 TILs.

15 . The method of claim 12 , wherein the therapeutically effective dosage in step (f) comprises from about 5×10 9 to about 1×10 10 TILs.

16 . The method of claim 12 , wherein the therapeutically effective dosage in step (f) comprises from about 1×10 10 to about 5×10 10 TILs.

17 . The method of claim 1 , wherein the first expansion is performed within a period of about 7 days.

18 . The method of claim 1 , wherein the second expansion is performed within a period of about 14 days.

19 . The method of claim 1 , wherein the first expansion is performed within a first period of about 7 days and the second expansion is performed within a second period of about 14 days.

20 . The method of claim 1 , wherein step (a) through step (b) are performed within a period of about 21 days.

21 . The method of claim 1 , wherein the first expansion is performed within a period of about 12 days.

22 . The method of claim 1 , wherein the second expansion is performed within a period of about 12 days.

23 . The method of claim 1 , wherein the first expansion is performed within a period of about 12 days and the second expansion is performed within a period of about 12 days.

24 . The method of claim 1 , wherein step (a) through step (b) are performed within a period of about 24 days.

25 . The method of claim 1 , wherein step (a) through step (b) are performed in a period of about 24 days.

26 . The method of claim 1 , wherein the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), renal cancer, and renal cell carcinoma.

27 . The method of claim 1 , wherein the cancer is a melanoma.

28 . The method of claim 1 , wherein prior to administering a therapeutically effective dosage of TIL cells in step (f), a non-myeloablative lymphodepletion regimen has been administered to the subject.

29 . The method of claim 28 , where the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg/m 2 /day for two days followed by administration of fludarabine at a dose of 25 mg/m 2 /day for five days.

30 . The method of claim 1 , further comprising the step of treating the subject with a high-dose IL-2 regimen starting on the day after administration of the TILs to the subject in step (f).

Assignees

• Iovance Biotherapeutics Inc

Inventors

• Wardell Seth
• Bender James

Classifications

• A61K40/4271

  Melanoma antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A01N1/162

  Temperature processes, e.g. following predefined temperature changes over time · CPC title

• C12N5/0635

  B lymphocytes · CPC title

• A61K2239/57

  Skin; melanoma · CPC title